(Q37728596)

22 August 2017

1 reference

title

The near future: improving the activity of rifamycins and pyrazinamide (English)

1 reference

22 August 2017

1 reference

ChEBI release 2020-05-28

D A Mitchison

1

1 reference

22 August 2017

P B Fourie

series ordinal

2

1 reference

22 August 2017

language of work or name

1 reference

9 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

90

1 reference

22 August 2017

3

1 reference

22 August 2017

177-181

1 reference

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Suitability of rifampicin for intermittent administration in the treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Antituberculosis drugs and hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Direct lung delivery of para-aminosalicylic acid by aerosol particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Nanoparticles for drug delivery to the lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Trojan particles: large porous carriers of nanoparticles for drug delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Clinical perspectives on pulmonary systemic and macromolecular delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Dexamethasone acetate encapsulation into Trojan particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

A practical approach to the use of nanoparticles for vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Inhaled drug delivery for tuberculosis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Oral solid lipid nanoparticle-based antitubercular chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.03.005

10.1016/J.TUBE.2010.03.005

7 January 2021

Identifiers

DOI

1 reference

release_xwzdzuipvbg2hlvhg6sxrmdv6e

22 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xwzdzuipvbg2hlvhg6sxrmdv6e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference